Urgell, AC, Garcia, O, Pena, E, Vilahur, G, Marques, GA. Long-term tissue factor expression orchestrates the angiogenic potential of adipose derived stem cells through par smad signaling and activin a cooperation. CARDIOVASCULAR RESEARCH. 2026; 122DOI:10.1093/cvr/cvag092.136. PMID:. IF:13.300(Q1/1D).

Dababneh, SF, Claydon, TW, Shafaattalab, S, Prondzynski, M, Kashihara, H, Hove-Madsen, L, Sanatani, S. In Memoriam: Glen F. PhD. CANADIAN JOURNAL OF CARDIOLOGY. 2026; 42(5)DOI:10.1016/j.cjca.2026.03.002. PMID:41796860. IF:5.300(Q1/2D).

Romero-Gómez, M, Escalada, J, Noguerol, M, Pérez, A, Carretero, J, Crespo, J, Mascort, JJ, Aguilar, I, Tinahone, F, Cañones, P, Gómez-Huelgas, R, de Luis, D, Trullos, IG, Aller, R, Rubio, MA, Calleja, JL. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis (vol 48, 502442. 2025). Gastroenterologia y Hepatologia. 2026; 49(5)DOI:10.1016/j.gastrohep.2025.502639. PMID:41571546. IF:1.900(Q3/7D).

Younossi, ZM, Yu, ML, de Avila, L, Petta, S, Hagström, H, Kim, SU, Nakajima, A, Crespo, J, Castera, L, Alkhouri, N, Zheng, MH, Treeprasertsuk, S, Ananchuensook, P, Shalimar, S, Tsochatzis, E, Shenoy, KT, Mohan, L, Fan, JG, Roberts, S, Alswat, KA, Wong, VWS, Yilmaz, Y, Dunn, W, Francque, S, Cordie, A, Alqahtani, S, Ekstedt, M, Goh, GBB, Oliveira, CP, Pessoa, M, Chan, WK, Fernández, MIC, Duseja, AK, Arab, JP, Papatheodoridis, G, Sebastiani, G, Villela-Nogueira, CA, D'Ambrosio, R, Lampertico, P, Al Naamani, K, Holleboom, AG, Valsan, A, Venu, A, El-Kassas, M, Pennisi, G, Shang, Y, Liu, WY, Lee, HW, Kobayashi, T, Kakizaki, S, Caussy, C, Pearlman, B, Iruzubieta, P, Nadeem, R, Cinque, F, Papatheodoridi, M, Zoncape, M, Yang, RX, Song, SJ, Dunn, N, Gadi, Z, Yeh, ML, Teh, KKJ, Mahadeva, S, Fabian, LG, Almohsen, A, Leite, N, Pugliese, N, Vessby, J, Xie, CC, Choudhary, NS, Friend, E, Poca, M, Kawaguchi, T, Russo, FP, Gadano, A, Diaz, LA, Singal, AK, Ségrestin, B, Gunn, N, Mauricio, D, Arrese, M, Fracanzani, AL, Lombardi, R, Aghemo, A, Zelber-Sagi, S, Lam, B, Racila, A, Stepanova, M. Liver fibrosis is the only predictor of adverse outcomes: time to remove metabolic dysfunction associated steatohepatitis (MASH) resolution as a clinical trial endpoint. JOURNAL OF HEPATOLOGY. 2026; 84DOI:. PMID:. IF:33.000(Q1/1D).